Ipilimumab/nivolumab
- PDF / 170,128 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 70 Downloads / 149 Views
1
S
Thyroid disorders and isolated adrenocorticotropic hormone deficiency: case report A man in his 50s [exact age at onset not stated] developed hypothyroidism, thyrotoxicosis, thyroiditis and isolated adrenocorticotropic hormone deficiency following treatment with ipilimumab and nivolumab for metastatic colon cancer. The man was diagnosed with colon cancer in 2015 at the age of 51-years. He started receiving treatment with ipilimumab and nivolumab [route and dose not stated] in 2017 following metastases to the liver. In February 2019, he developed transient thyrotoxicosis (769 days after initiation of ipilimumab and nivolumab), TSH was 0.03 mIU/L and free T4 was 2.58 ng/dL. He was diagnosed with thyroiditis. In April 2019, he developed hypothyroidism, TSH was 12.64 mIU/L and free T4 was 0.39 ng/dL. At this time, he had developed nausea, weight loss and fatigue. Further laboratory studies revealed adrenocorticotropic hormone level of
Data Loading...